Mankind Pharma Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Mankind Pharma stock has a consensus rating of "Buy" and an average price target of ₹2,653. The average 1-year stock price forecast is 9.91% higher than the current stock price, while the lowest is ₹1,990 (-17.57%) and the highest is ₹3,100 (+28.41%).

Price Target: ₹2,653 (+9.91%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	₹1,990	₹2,653	₹2,727	₹3,100
Change	-17.57%	+9.91%	+12.96%	+28.41%

Analyst Ratings

The average analyst rating for Mankind Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	9	8	8	8	7	7
Buy	6	7	8	8	8	8
Hold	1	1	1	1	1	1
Sell	1	2	2	2	3	3
Strong Sell	1	1	1	1	1	1
Total	18	19	20	20	20	20

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst Bernstein No rating	Bernstein	Sell Maintains ₹2,057	Sell	Maintains	₹2,057	-14.80%	Jun 3, 2026
Bansi Desai J.P. Morgan	J.P. Morgan	Buy Maintains ₹2,850	Buy	Maintains	₹2,850	+18.05%	May 22, 2026
Alok Dalal Jefferies	Jefferies	Buy Maintains ₹3,000	Buy	Maintains	₹3,000	+24.26%	May 21, 2026
Tushar Manudhane Motilal Oswal	Motilal Oswal	Buy Reiterates ₹2,640	Buy	Reiterates	₹2,640	+9.35%	Apr 29, 2026

Financial Forecast

Revenue This Year

159.87B

from 142.78B

11.97%

from 142.78B

Revenue Next Year

177.74B

from 159.87B

11.17%

from 159.87B

EPS This Year

57.38

from 51.96

10.43%

from 51.96

EPS Next Year

71.70

from 57.38

24.96%

from 57.38

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	77.82B	87.49B	102.60B	122.07B	142.78B	159.87B
Revenue Growth	25.22%	12.44%	17.27%	18.98%	16.96%	11.97%
Gross Profit	52.94B	57.46B	69.55B	85.48B	102.26B	114.59B
Gross Margin	68.03%	65.68%	67.78%	70.02%	71.62%	71.68%
Operating Income	18.32B	15.88B	21.50B	24.07B	27.31B	32.46B
Net Income	14.33B	12.82B	19.13B	19.91B	19.13B	23.56B
EPS	-	-	-	-	51.96	57.38
EPS Growth	-	-	-	-	5.87%	10.43%
Forward PE	-	-	43.88	45.13	35.54	42.07
Free Cash Flow	-16.38B	7.12B	12.64B	7.65B	16.48B	23.75B
No. Analysts	-	-	-	-	-	18

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.

Revenue Forecast

Revenue	2027	2028	2029
High	164.9B
Avg	159.9B
Low	157.5B

Revenue Growth

Revenue Growth	2027	2028	2029
High	15.5%
Avg	12.0%
Low	10.3%

EPS Forecast

EPS	2027	2028	2029
High	62.80
Avg	57.38
Low	51.70

EPS Growth

EPS Growth	2027	2028	2029
High	20.9%
Avg	10.4%
Low	-0.5%